Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 17/20 | 0.70 |
| ▸ | MAPK12 | P53778 | 17/20 | 0.70 |
| ▸ | MAPK11 | Q15759 | 17/20 | 0.70 |
| ▸ | MAPK14 | Q16539 | 17/20 | 0.70 |
| ▸ | RAF1 | P04049 | 9/20 | 0.70 |
| ▸ | GCGR | P47871 | 8/20 | 0.68 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.63 |
| ▸ | BRAF | P15056 | 3/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | TEK | Q02763 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2948138 | 0.93 | MAPK13 (0.58) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL6467708 | 0.92 | MAPK14 (0.72) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL28397228 | 0.90 | MAPK13 (0.70) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL29732583 | 0.88 | MAPK13 (0.60) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL20504034 | 0.88 | MAPK13 (0.60) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL2649377 | 0.88 | MAPK14 (0.73) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL6468974 | 0.87 | MAPK14 (0.80) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL5198574 | 0.84 | MAPK14 (0.73) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL6465619 | 0.83 | MAPK13 (0.90) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL6469111 | 0.82 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203155-A1 | Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections | AXXIMA PHARMACEUTICAL AG. (DE) | 2005-09-15 | — | — | US | claimed |
| EP-1532118-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2005-05-25 | — | — | EP | claimed |
| WO-2004005264-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | AXXIMA PHARMACEUTICALS AG (DE) | 2004-01-15 | — | — | WO | claimed |
| US-20240000821-A1 | CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER | UNIV JOHNS HOPKINS (US) | 2024-01-04 | — | — | US | disclosed |
| US-20200078387-A1 | CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER | THE JOHNS HOPKINS UNIVERSITY | 2020-03-12 | — | — | US | disclosed |
| WO-2018112342-A1 | CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20050203155-A1 | Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections | AXXIMA PHARMACEUTICAL AG. (DE) | 2005-09-15 | — | — | US | disclosed |
| EP-1532118-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004005264-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | AXXIMA PHARMACEUTICALS AG (DE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203155-A1 | Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections | CSNK1G1, CSNK1E, CSNK1D | MAPK13 456/4885MAPK12 732/4885MAPK11 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.